Peptide regulation made a lot of headlines in 2026. Most of them were more confident than the underlying facts. Here's the calmer version.
The July vote was a recommendation, not a decision. An FDA advisory committee voted to recommend adding six peptides to the list of substances pharmacies may legally compound. Advisory committee votes are formally non-binding: the FDA's own staff had recommended against this particular addition, and the agency is not required to follow the committee's recommendation. As of this writing, no rule has changed. Nothing is different until formal rulemaking actually happens, which can take months or longer and includes its own public comment process.
Leaving "Category 2" isn't approval. In April 2026, twelve peptides were removed from the FDA's list of compounds with significant safety concerns (informally, "Category 2"), after the nominations that had placed them there were withdrawn. That move takes those compounds out of a specific safety-concern category; it does not authorize them for compounding, sale, or any other use. Absence from a concern list is not the same as a green light.
"Research use only" still isn't a legal shield. See the companion piece on what that label actually does and doesn't cover.
The throughline across all three: regulatory status in this space moves in small, specific, procedural steps, and almost none of them are the dramatic "it's legal now" or "it's banned now" that headlines imply. BioBonds updates this page whenever that status actually changes, with the date of the last review shown at the top.